What the FDA labels say about taking them together
Bromocriptine and octreotide
Octreotide's FDA label of July 22, 2026 names bromocriptine in its drug interactions section; the bromocriptine labels PlainMeds reads (2) do not name octreotide. The octreotide label: “Bromocriptine: dose adjustment of bromocriptine may be necessary ( 7 ).”
Check it at the source: the bromocriptine FDA label on DailyMed (effective July 27, 2026, ANI Pharmaceuticals, Inc.); the octreotide FDA label on DailyMed (effective July 22, 2026, Novartis Pharmaceuticals Corporation).
What does the bromocriptine label say about octreotide?
Bromocriptine's label (effective July 27, 2026) and its 1 other brand-application label do not name octreotide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Bromocriptine Mesylate), ANI Pharmaceuticals, Inc., effective July 27, 2026 (SPL set 17f3a343-1782-4799-95ba-31dfe93be2cf), via openFDA; the full label on DailyMed
What does the octreotide label say about bromocriptine?
Octreotide label, drug interactionsConcomitant administration of octreotide and bromocriptine increases the availability of bromocriptine.
Mycapssa label (Chiesi USA, Inc., July 24, 2025), drug interactionsBromocriptine: dose adjustment of bromocriptine may be necessary ( 7 ).
Bynfezia Pen label (Sun Pharmaceutical Industries, Inc., February 21, 2025), drug interactionsDRUG INTERACTIONS The following drugs require monitoring and possible dose adjustment when used with BYNFEZIA PEN : cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. (7) Lutetium Lu 177 Dotatate Injection:
Source: FDA drug label (Mycapssa, NDA208232), Chiesi USA, Inc., effective July 24, 2025 (SPL set 58d80bc6-bdfb-4908-93e7-aace447c8d1a), via openFDA
Source: FDA drug label (Bynfezia Pen, NDA213224), Sun Pharmaceutical Industries, Inc., effective February 21, 2025 (SPL set 20ed4e79-ad4c-426f-859d-83790c00439b), via openFDA
Source: FDA drug label (Sandostatin), Novartis Pharmaceuticals Corporation, effective July 22, 2026 (SPL set 4e2c9856-1836-49f0-9472-4dbeeb408f39), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Bromocriptine | Octreotide | |
|---|---|---|
| Labeled for | Parkinson's disease, Type 2 diabetes | Diarrhea |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $1.61 per tablet 2.5 mg tablet | $2.53 per mL 100 mcg/mL vial |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once